Lafayette Investments Inc. Raises Position in Novo Nordisk A/S $NVO

Lafayette Investments Inc. increased its stake in Novo Nordisk A/S (NYSE:NVO) by 44.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 68,845 shares of the company’s stock after purchasing an additional 21,091 shares during the quarter. Lafayette Investments Inc.’s holdings in Novo Nordisk A/S were worth $3,820,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC lifted its position in shares of Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after buying an additional 2,274,925 shares during the last quarter. Bank of Montreal Can raised its stake in Novo Nordisk A/S by 101.4% in the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after acquiring an additional 1,246,467 shares during the period. DAVENPORT & Co LLC lifted its holdings in Novo Nordisk A/S by 54.8% during the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock valued at $146,644,000 after purchasing an additional 935,468 shares during the last quarter. Sustainable Growth Advisers LP boosted its position in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after purchasing an additional 649,390 shares during the period. Finally, Baird Financial Group Inc. increased its stake in shares of Novo Nordisk A/S by 42.6% in the second quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock worth $101,920,000 after purchasing an additional 441,034 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $48.91 on Friday. The company’s fifty day moving average price is $53.71 and its 200-day moving average price is $53.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market capitalization of $218.39 billion, a price-to-earnings ratio of 14.10 and a beta of 0.67. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo is planning to roll out Wegovy in vial format (and other device presentations), which could broaden distribution channels, improve dosing flexibility and help meet demand amid intense competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: CEO Mike Doustdar highlighted a potential ~15 million-patient Medicare opportunity once obesity treatments gain coverage — a large TAM that supports long-term revenue upside if access improves. Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
• Positive Sentiment: A study found many Wegovy pill users are new to GLP‑1 therapies, suggesting the product is expanding the market rather than only cannibalizing existing diabetes/weight-loss patients. That supports growth potential if retention and outcomes hold. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Coverage on how Novo is expanding its global healthcare reach highlights strategic initiatives and portfolio breadth, but offers limited immediate impact to near-term earnings. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Coverage comparing Eli Lilly and Novo Nordisk notes intense competition in the weight‑loss market; investors should watch share shifts but the piece is a market-context update rather than firm-specific news. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here’s What Investors Need to Know.
• Neutral Sentiment: Company disclosure of insider trading by board members/executives was published; routine regulatory reporting that bears watching only if it signals large directional bets. Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
• Negative Sentiment: Regulatory pressure is mounting: the FDA flagged a TV ad for the Wegovy pill as misleading and broader reporting highlights potential FDA warnings and lawsuits — these raise reputational, marketing and legal risk that could dent demand or increase costs. Novo’s TV ad for Wegovy pill was misleading, FDA says FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story
• Negative Sentiment: Analysts are turning cautious: Deutsche Bank cut its price target ~16% citing revenue headwinds and risks, and Zacks downgraded Novo to a “strong sell” — analyst actions can pressure sentiment and share price near term. Novo Nordisk target cut by Deutsche Bank despite long-term optimism Zacks Research downgrade

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Morgan Stanley reaffirmed an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Citigroup started coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. CICC Research began coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $56.07.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.